BRPI0810161A2 - Composto, preparação farmacêutica, composição farmacêutica, e, uso de um composto - Google Patents

Composto, preparação farmacêutica, composição farmacêutica, e, uso de um composto

Info

Publication number
BRPI0810161A2
BRPI0810161A2 BRPI0810161A BRPI0810161A2 BR PI0810161 A2 BRPI0810161 A2 BR PI0810161A2 BR PI0810161 A BRPI0810161 A BR PI0810161A BR PI0810161 A2 BRPI0810161 A2 BR PI0810161A2
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutical
pharmaceutical composition
pharmaceutical preparation
preparation
Prior art date
Application number
Other languages
English (en)
Portuguese (pt)
Inventor
Hakan V Wikstroem
Original Assignee
Nsab Af Neurosearch Sweden Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nsab Af Neurosearch Sweden Ab filed Critical Nsab Af Neurosearch Sweden Ab
Publication of BRPI0810161A2 publication Critical patent/BRPI0810161A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/94—Oxygen atom, e.g. piperidine N-oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Anesthesiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0810161 2007-04-12 2008-04-11 Composto, preparação farmacêutica, composição farmacêutica, e, uso de um composto BRPI0810161A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0700893 2007-04-12
PCT/SE2008/050414 WO2008127188A1 (en) 2007-04-12 2008-04-11 N-oxide and/or di-n-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles

Publications (1)

Publication Number Publication Date
BRPI0810161A2 true BRPI0810161A2 (pt) 2014-12-30

Family

ID=39864178

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0810161 BRPI0810161A2 (pt) 2007-04-12 2008-04-11 Composto, preparação farmacêutica, composição farmacêutica, e, uso de um composto

Country Status (19)

Country Link
US (1) US9139525B2 (enExample)
EP (1) EP2146961B1 (enExample)
JP (1) JP5393654B2 (enExample)
CN (1) CN101711236B (enExample)
AU (1) AU2008239841B2 (enExample)
BR (1) BRPI0810161A2 (enExample)
CA (1) CA2683719C (enExample)
CY (1) CY1115337T1 (enExample)
DK (1) DK2146961T3 (enExample)
ES (1) ES2458592T3 (enExample)
HR (1) HRP20140380T1 (enExample)
IL (1) IL201401A (enExample)
MX (1) MX2009011020A (enExample)
NZ (1) NZ580856A (enExample)
PL (1) PL2146961T3 (enExample)
PT (1) PT2146961E (enExample)
RU (1) RU2470013C2 (enExample)
SI (1) SI2146961T1 (enExample)
WO (1) WO2008127188A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
EP2367788A1 (en) * 2008-11-24 2011-09-28 NSAB, Filial af NeuroSearch Sweden AB, Sverige 3-phenyl-3-methoxypyrrolidine derivatives as modulators of cortical catecholaminergic neurotransmission
WO2011107583A1 (en) 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
BR112013005125A2 (pt) 2010-09-03 2016-08-16 Ivax Int Gmbh deuterados análogos dos pridopidine úteis como estabilizadores dopaminérgicos
US9018202B2 (en) * 2010-12-03 2015-04-28 Allergan, Inc. Methods for treating diseases of the retina
CA2847736A1 (en) 2011-09-07 2013-03-14 IVAX International GmbH A new polymorphic form of pridopidine hydrochloride
MX347209B (es) 2011-12-08 2017-04-19 Teva Pharmaceuticals Int Gmbh La sal de bromhidrato de pridopidina.
US20130267552A1 (en) 2012-04-04 2013-10-10 IVAX International GmbH Pharmaceutical compositions for combination therapy
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
JP2016523862A (ja) 2013-06-21 2016-08-12 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーＴｅｖａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ ハンチントン病を治療するための高用量プリドピジンの使用
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
CA2970799A1 (en) 2014-12-22 2016-06-30 Teva Pharmaceuticals International Gmbh L-tartrate salt of pridopidine
US11471449B2 (en) 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
HUE060353T2 (hu) 2015-02-25 2023-02-28 Prilenia Neurotherapeutics Ltd Pridopidin alkalmazása memória javítására
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
JP7034488B2 (ja) 2016-02-24 2022-03-14 プリレニア・ニューロセラピューティクス・エルティーディー プリドピジンを使用する神経変性眼疾患の治療
CA3035099C (en) 2016-08-24 2023-01-17 Prilenia Therapeutics Development Ltd. Use of pridopidine for treating dystonias
HUE071008T2 (hu) 2016-08-24 2025-07-28 Prilenia Neurotherapeutics Ltd Pridopidin alkalmazása mûködési hanyatlás kezelésére
US12102627B2 (en) 2016-09-16 2024-10-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
IL268125B2 (en) 2017-01-20 2023-04-01 Prilenia Neurotherapeutics Ltd Pridopidine for the treatment of fragile x syndrome
HUE061505T2 (hu) 2017-08-14 2023-07-28 Prilenia Neurotherapeutics Ltd Módszer amyothrophiás lateralsclerosis kezelésére pridopidinnel
EA202090542A1 (ru) 2017-08-30 2020-06-08 Приления Ньюротерапьютикс Лтд. Высококонцентрированные лекарственные формы придопидина
AU2018329628B2 (en) 2017-09-08 2021-04-22 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
US12036213B2 (en) 2017-09-08 2024-07-16 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
CN113395964A (zh) 2019-02-04 2021-09-14 普瑞尼亚神经治疗有限公司 用于帕金森氏病和与帕金森症相关的其它疾病的低剂量普利多匹定
CN116472043A (zh) * 2020-10-20 2023-07-21 普瑞尼亚神经治疗有限公司 普利多匹定和类似物用于治疗焦虑和抑郁的用途

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1217296A (en) 1917-01-11 1917-02-27 Lewis A Peckham Shock-absorber.
US2813098A (en) 1955-08-16 1957-11-12 Upjohn Co 3-methoxy-n-methylmorphinan n-oxide
US2813097A (en) 1955-08-16 1957-11-12 Upjohn Co 3-hydroxy-n-methylmorphinan-n-oxide
US3131185A (en) 1959-03-18 1964-04-28 Orsymonde Nicotinic esters of hydroxyl derivatives of the phenanthrenic alkaloids of opium, and process for the preparation of these esters
BE638369A (enExample) 1962-10-10
CH481123A (de) 1966-09-21 1969-11-15 Geigy Ag J R Verfahren zur Herstellung von neuen, kondensierten heterocyclischen Verbindungen
CA2071897A1 (en) 1989-12-28 1991-06-29 Richard A. Glennon Sigma receptor ligands and the use thereof
AU653837B2 (en) * 1991-04-17 1994-10-13 Pharmacia & Upjohn Company Substituted phenylazacycloalkanes as CNS agents
PT100639A (pt) 1991-06-27 1993-09-30 Univ Virginia Commonwealth Metodo para o tratamento terapeutico com compostos que sao ligandos ao receptor sigma e compostos ai utilizados, nomeadamente derivados fenilalquil-amina, aminotetralina,piperazina e piperidina
IL112099A (en) * 1993-12-23 1999-07-14 Ortho Pharma Corp N-oxides of 4-arylpiperazines and 4-arylpiperidines and pharmaceutical compositions containing them
CA2144669A1 (en) 1994-03-29 1995-09-30 Kozo Akasaka Biphenyl derivatives
DE69912635T2 (de) * 1998-11-23 2004-05-13 Sepracor Inc., Marlborough Olanzapin-n-oxide enthaltende pharmaceutische zusammensetzungen
SE9904723D0 (sv) * 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission II
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
SE0200301D0 (sv) 2002-02-01 2002-02-01 Axon Biochemicals Bv Thio-carbostyril derivative
DE602005017784D1 (de) * 2004-06-08 2009-12-31 Nsab, Filial Af Neurosearch Sweden Ab Neue disubstituierte phenylpiperidine als modulatoren der dopamin- und serotoninneurotransmission
ATE469885T1 (de) 2004-06-08 2010-06-15 Nsab Af Neurosearch Sweden Ab Neue disubstituierte phenylpiperidine und piperazine als modulatoren der dopamin- neurotransmission
AU2005273961A1 (en) * 2004-08-11 2006-02-23 Williamsburg Holdings Llc Noncardiotoxic pharmaceutical compounds
DK1802573T3 (en) * 2004-10-13 2016-12-19 Teva Pharmaceuticals Int Gmbh METHOD OF SYNTHESIS OF 4- (3-METHANSULPHONYLPHENYL) -1-N-PROPYL-PIPERIDINE.
JP2009504799A (ja) 2005-08-22 2009-02-05 ソルベイ・フアーマシユーチカルズ・ベー・ブイ ピペラジンおよびピペリジン誘導体のプロドラッグとしてのｎ−オキシド
SE529246C2 (sv) * 2005-10-13 2007-06-12 Neurosearch Sweden Ab Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
CN101432279A (zh) * 2006-05-02 2009-05-13 索尔瓦药物有限公司 吡啶基甲基哌嗪和吡啶基甲基哌啶衍生物的n-氧化物
WO2011107583A1 (en) * 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
US20130203886A1 (en) * 2010-03-05 2013-08-08 Nileshkumar Prakash Kukalyekar Process for the production of an uhmwpe article
BR112013005125A2 (pt) * 2010-09-03 2016-08-16 Ivax Int Gmbh deuterados análogos dos pridopidine úteis como estabilizadores dopaminérgicos
CA2847736A1 (en) 2011-09-07 2013-03-14 IVAX International GmbH A new polymorphic form of pridopidine hydrochloride
MX347209B (es) * 2011-12-08 2017-04-19 Teva Pharmaceuticals Int Gmbh La sal de bromhidrato de pridopidina.
US20130267552A1 (en) * 2012-04-04 2013-10-10 IVAX International GmbH Pharmaceutical compositions for combination therapy
MX2015003812A (es) * 2012-09-27 2015-07-17 Teva Pharma Combinacion de rasagilina y pridopidina para tratar trastornos neurodegenerativos, en particular enfermedad de huntington.
EA201590655A8 (ru) * 2012-09-27 2016-07-29 Тева Фармасьютикал Индастриз Лтд. Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений

Also Published As

Publication number Publication date
IL201401A0 (en) 2010-05-31
NZ580856A (en) 2011-11-25
PT2146961E (pt) 2014-04-30
RU2470013C2 (ru) 2012-12-20
IL201401A (en) 2015-10-29
PL2146961T3 (pl) 2014-09-30
ES2458592T3 (es) 2014-05-06
WO2008127188A1 (en) 2008-10-23
US9139525B2 (en) 2015-09-22
SI2146961T1 (sl) 2014-08-29
AU2008239841B2 (en) 2013-07-18
EP2146961B1 (en) 2014-01-29
DK2146961T3 (da) 2014-04-28
EP2146961A4 (en) 2011-08-03
JP2010523651A (ja) 2010-07-15
CN101711236B (zh) 2012-10-31
JP5393654B2 (ja) 2014-01-22
CN101711236A (zh) 2010-05-19
RU2009141300A (ru) 2011-05-20
AU2008239841A1 (en) 2008-10-23
CA2683719C (en) 2015-07-14
EP2146961A1 (en) 2010-01-27
HRP20140380T1 (hr) 2014-08-15
US20100105736A1 (en) 2010-04-29
CA2683719A1 (en) 2008-10-23
CY1115337T1 (el) 2017-01-04
MX2009011020A (es) 2009-10-30

Similar Documents

Publication Publication Date Title
BRPI0810161A2 (pt) Composto, preparação farmacêutica, composição farmacêutica, e, uso de um composto
BRPI0810696A2 (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0919942A2 (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0907562A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0921375A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0815709A2 (pt) composro, composição farmacêutica, e, uso de um composto.
BRPI0921879A2 (pt) composto, composição farmacêutica , e, uso de um composto
BRPI1016219A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI1008793A2 (pt) composto, uso de um composto, e, composição farmacêutica
BRPI0917579A2 (pt) composto, composição farmacêutica, métodos, e, uso de um composto
BRPI0821115A2 (pt) Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto
BRPI0812942A2 (pt) Composto, composição farmacêutica e uso de um composto
BRPI0810019A2 (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0716171A2 (pt) composto, composiÇço farmacÊutica e uso de um composto.
BRPI0819696A2 (pt) Compostos de derivados de 2-fenil-pirimidina, composição farmacêutica e uso de um composto
BRPI1007018A2 (pt) composto, composição farmacêutica, e , uso de um composto.
BRPI0609802A2 (pt) composto, composição farmacêutica e uso de um composto
BRPI1008906A2 (pt) composto, composição farmacêutica, e, uso de um composto.
BRPI0906937A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0716698A2 (pt) Composto, composição farmacêutica e uso de um composto
BRPI0818193A2 (pt) composto, sal farmacêuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto
BRPI0917001A2 (pt) composto, composição farmacêutica, e, uso de um composto ou uma composição farmacêutica
BR112013008259A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0915473A2 (pt) composto, composição farmacêutica, e, uso de um composto
BR112013015397A2 (pt) composto, composição farmacêutica, e, uso de um composto

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: IVAX INTERNATIONAL GMBH (CH)

B25G Requested change of headquarter approved

Owner name: IVAX INTERNATIONAL GMBH (CH)

B25D Requested change of name of applicant approved

Owner name: TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2509 DE 05-02-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.